David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

NZ sharemarket rises on back of positive news
Markets Market close

NZ sharemarket rises on back of positive news

The S&P/NZX 50 Index closed at 13,041.9, rising 276.66 points or 2.17%

Graham Skellern 22 Nov 2024
Oceania shrinks footprint, prioritises balance sheet
Property

Oceania shrinks footprint, prioritises balance sheet

Oceania has divested four aged care facilities in the space of six months.

Gregor Thompson 22 Nov 2024
The Warehouse’s plan to come back ‘with a vengeance’
Retail

The Warehouse’s plan to come back ‘with a vengeance’

Executives face tough questions at the retailer’s AGM.

Victoria Young 22 Nov 2024
Wellington's blue sky boondoggle
Infrastructure

Pattrick Smellie: Wellington's blue sky boondoggle

Is the capital's airport serious, or is Infratil just trying to pump value?

Pattrick Smellie 22 Nov 2024